OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Burnham on Health Disparities in Prostate Cancer

July 14th 2021

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

Dr. O’Malley on the Promise of Antibody-Drug Conjugates in Ovarian Cancer

July 14th 2021

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

July 14th 2021

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Dr. Miller on the Safety, Efficacy of Veliparib Vs Other PARP Inhibitors in Ovarian Cancer

July 14th 2021

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Tagawa on the Utility of Radium-223 in Prostate Cancer

July 14th 2021

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian Cancer

July 14th 2021

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Dr. Dreicer on the Initial Findings With Sabizabulin in mCRPC

July 13th 2021

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Dr. Ghia on the Clinical Implications of the CAPTIVATE Trial in CLL

July 13th 2021

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Kumar on Integrating CAR T-Cell Therapy Into Heavily Pretreated Multiple Myeloma

July 13th 2021

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Dr. Pollyea on Improving Outcomes With Induction Chemotherapy in AML

July 13th 2021

Daniel Pollyea, MD, MS, discusses improving induction outcomes for newly diagnosed patients with acute myeloid leukemia.

Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS

July 12th 2021

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment

July 12th 2021

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

July 12th 2021

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 12th 2021

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Dr. Jones on the Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in CRC

July 12th 2021

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Dr. Pothuri on Treatment Considerations for PARP Inhibitors in Ovarian Cancer

July 12th 2021

Bhavana Pothuri, MD, discusses treatment considerations for PARP inhibitors in patients with ovarian cancer.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

July 10th 2021

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Dr. Sperling on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

July 9th 2021

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Dr. Tagawa on Tumor Targeting With Radionuclides in Prostate Cancer

July 8th 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.